Apex Innovative Sciences and the company’s affiliates announced their participation in three Covid-19 vaccine studies.

The Centers for Disease Control and Prevention had administered 2,589,125 first doses of Covid-19 vaccines in the United States as of the morning of Dec. 30 and distributed 12,409,050 doses.

European Medicines Agency

The European Union was asked to allow an extra dose of the Covid-19 vaccine developed by Pfizer and BioNTech to be taken from each vial, a practice allowed elsewhere that would make scarce supplies go further.

A vaccine being developed by the Nanovaccine Institute at Iowa State University (ISU) will be able to be administered without needles and in one dose.

Pfizer, COVID vaccine

Europe launched a cross-border vaccination program of unprecedented scale on Dec. 27 as part of efforts to end the Covid-19 pandemic that has crippled economies and claimed more than 1.7 million lives around the world.

Millions of Covid-19 vaccines were sitting unused in U.S. hospitals and elsewhere a week into the massive inoculation campaign, putting the government’s target for 20 million vaccinations during December in doubt.

Pfizer and BioNTech reached an agreement with the Trump administration on supplying more of their Covid-19 vaccine.

European Medicines Agency

Europe’s medicines regulator approved the use of the Covid-19 vaccine developed by U.S. company Pfizer and its German partner BioNTech, putting the EU on course to start inoculations within a week.

The first injections of Moderna’s Covid-19 vaccine started to be administered on Dec. 21 after the U.S. Food and Drug Administration granted Emergency Use Authorization (EUA) on Dec. 18.

Global coronavirus infections surpassed the 75 million mark on Dec. 19, according to a Reuters tally, as several nations around the world begin vaccinating against the virus.